Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.59 USD | -0.62% | -4.79% | +2.58% |
Financials (USD)
Sales 2024 * | 94.02M | Sales 2025 * | 72.9M | Capitalization | 108M |
---|---|---|---|---|---|
Net income 2024 * | -24M | Net income 2025 * | -43M | EV / Sales 2024 * | 1.15 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 1.49 x |
P/E ratio 2024 * |
-5.52
x | P/E ratio 2025 * |
-4.23
x | Employees | 121 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.81% |
Latest transcript on CytomX Therapeutics, Inc.
1 day | -0.63% | ||
1 week | -4.79% | ||
Current month | -27.06% | ||
1 month | -27.40% | ||
3 months | -1.24% | ||
6 months | +48.60% | ||
Current year | +2.58% |
Managers | Title | Age | Since |
---|---|---|---|
Sean McCarthy
CEO | Chief Executive Officer | 57 | 10-11-30 |
Chris Ogden
DFI | Director of Finance/CFO | 40 | 21-08-01 |
Marcia Belvin
CTO | Chief Tech/Sci/R&D Officer | 57 | 17-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
James Meyers
BRD | Director/Board Member | 58 | 18-12-19 |
Elaine Jones
BRD | Director/Board Member | 69 | 14-11-30 |
Sean McCarthy
CEO | Chief Executive Officer | 57 | 10-11-30 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.01% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-25 | 1.6 | -1.84% | 286,317 |
24-04-24 | 1.63 | -2.98% | 350,911 |
24-04-23 | 1.68 | +0.60% | 290,181 |
24-04-22 | 1.67 | 0.00% | 257,899 |
24-04-19 | 1.67 | -3.47% | 505,550 |
Delayed Quote Nasdaq, April 26, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+2.58% | 108M | |
-2.31% | 103B | |
+0.56% | 95.71B | |
+1.69% | 22.02B | |
-17.37% | 20.9B | |
-9.30% | 17.85B | |
-41.01% | 16.21B | |
-14.85% | 15.52B | |
+3.21% | 13.86B | |
+33.54% | 12.04B |
- Stock Market
- Equities
- CTMX Stock